Mary Ann Liebert: Results of the INHALE-3 Extension Study - Inhaled Technosphere Insulin Plus Insulin Degludec in T1D
March 21, 2025
March 21, 2025
NEW ROCHELLE, New York, March 21 -- Mary Ann Liebert Inc. issued the following news release:
* * *
Results of the INHALE-3 Extension Study: Inhaled Technosphere Insulin Plus Insulin Degludec in T1D
New Rochelle, NY, March 20, 2025--A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its potential to reduce post-mea . . .
* * *
Results of the INHALE-3 Extension Study: Inhaled Technosphere Insulin Plus Insulin Degludec in T1D
New Rochelle, NY, March 20, 2025--A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its potential to reduce post-mea . . .